Navigation Links
Curaxis Pharmaceutical Corp Confirms Exploration of Frankfurt Exchange Listing

DURHAM, N.C., Jan. 10, 2011 /PRNewswire/ -- Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corp (OTC Bulletin Board: CURX), confirmed today that Curaxis is exploring listing its shares on the Frankfurt stock exchange during the next several weeks as part of a planned multi-city European roadshow to meet with prospective European investors.

Mr. Smith noted, "Based on our analysis, we believe that listing on the Frankfurt exchange will give us access to European investors who are hesitant to invest in United States OTC stocks in the absence of a Frankfurt listing. We expect to discuss the listing with European investors and advisors during the next several weeks."

About Curaxis

Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease and multiple cancers. Curaxis' therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers.

Notice Regarding Forward Looking Statements

This press release includes certain "Forward-Looking Statements" within the meaning of section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding potential results and future plans and objectives of Curaxis Pharmaceutical Corporation are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the Securities and Exchange Commission. Other risk factors may include, but are not limited to, fluctuation in quarterly results, and increased competition in our operations, our ability to continue operations as scheduled, and our ability to protect the proprietary technology we use. Further, the company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the company's control, such as announcements by competitors and service providers.

The contents of this press release are presented as a general overview of the company. It is intended only to contain general information regarding the company and its business and does not purport to provide complete disclosure or analysis of all matters, which may be relevant to a decision to make an investment, including all risk factors or similar considerations. Although the information is believed current as of the date herein, the information may be subject to change, amendment or supplementation, and the company does not expect, and assumes no obligation, to update or otherwise revise the information herein.

SOURCE Curaxis Pharmaceutical Corp
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
2. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
3. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
4. Optimer Pharmaceuticals Announces Key Additions to Management Team
5. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
7. OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5
8. Questcor Pharmaceuticals Reports Strong Finish to 2010
9. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
10. Endo Pharmaceuticals Provides Regulatory Update on New Formulation of OPANA® ER Designed to be Crush-Resistant
11. Tianyin Pharmaceutical to Hold 2010 Shareholder Annual Meeting on March 21, 2011 at NYSE
Post Your Comments:
(Date:10/12/2015)... Va. , Oct. 12, 2015  Today, Divurgent is ... of Advisory Services. As a former CIO, Paul brings 15 ... not just understand or sympathize with today,s CIOs, he is ... the same challenges Paul has faced, and his new role ... in ensuring technology efficiencies across an organization. ...
(Date:10/12/2015)... DENVER , Oct. 12, 2015 Beginning ... ICD-10 Codes. Therapy Partner, the fastest growing practice management ... automated technology that easily converts all patient diagnostic codes ... --> --> ... Brief for all mental health practitioners to easily understand ...
(Date:10/12/2015)... INDIANAPOLIS , Oct. 12, 2015 Eli ... ACCELERATE study,s academic leadership have accepted the recommendation of ... 3 trial of the investigational medicine evacetrapib, due to ... the treatment of high-risk atherosclerotic cardiovascular disease and will ... --> --> The independent data ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe dentists’ office, ... IV sedation dentistry for more than 5 years. A leading cause of emergency ... painful if treatment is not timely. , Sedation dentistry provides an ...
(Date:10/13/2015)... Wyoming (PRWEB) , ... October 13, 2015 , ... Local ... the Gold’s Gym International Conference on August 26. Berry, who owns and operates ... standards for the fastest growing Gold’s Gyms in the United States. A brand leader ...
(Date:10/13/2015)... ... October 13, 2015 , ... Thermi, an award-winning and ... to introduce the latest development, ThermiVa® temperature controlled radiofrequency to the medical community. ... Obstetrics and Gynecology and a pioneer in the field of laparoscopy. On June ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an ongoing effort ... , a Southlake, Texas, child development and pediatric therapy center, is working with ... families about their options for receiving this kind of care for affected children. ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Just under ... would-be customers, eMarketing Concepts began a $1 promotion – effectively offering all of their ... success, and within weeks the company was flooded with phone calls from interested buyers. ...
Breaking Medicine News(10 mins):